PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Ophthalmic Pharmaceuticals Enjoy Good Potential in South Africa - With a substantial number of established companies participating in this sector, the South African ophthalmic pharmaceuticals market is in a growth stage
Ophthalmic Pharmaceuticals Enjoy Good Potential in South Africa


NewswireToday - /newswire/ - Cape Town, South Africa, 2008/07/21 - With a substantial number of established companies participating in this sector, the South African ophthalmic pharmaceuticals market is in a growth stage.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


However, the limited number of suitably qualified professionals in the country and inadequate financial resources available to households may dampen prospects.

New analysis from Frost & Sullivan (, South African Ophthalmology Pharmaceuticals Market, finds that the market earned revenues of $38.4 million in 2007 and estimates this to reach $63.4 million in 2013.

"South Africa's 47.2 million people provide a solid market for ophthalmologic pharmaceuticals," notes Frost & Sullivan Research Analyst Tiwonge Mkandawire. "Expanded medical insurance coverage as well as a general increase in capacity to pay for heath services will result in growth in revenues for in this sector. In addition, there is a general rise in awareness about health issues and treatment options because of easier access to information."

Currently, only 15 per cent of the country's population has medical aid cover. The high enrolment rate onto the Government Employees Medical Scheme (GEMS) is however set to increase the number of people under medical insurance from 7 million to 8 million in the near future. Additionally, low-cost medical insurance companies are allowing a growing proportion of the population access to private health services.

Efforts by the department of health to ensure the availability of cheap healthcare however have the potential to dampen growth in the healthcare industry as a whole. Following the introduction of Single Exit Pricing (SEP) and benchmarking for pharmaceuticals in 2004, the government has stated its intentions of regulating the private healthcare market. This further control on prices, coupled with fluctuations in the country's economy, will present a challenge to companies seeking to penetrate the market.

"The limited number of specialists available for the prescription of ethical products has an additional bottleneck effect on potential revenues that could be generated in the ophthalmic market," remarks Mkandawire. "Currently, there are only 348 registered ophthalmologists in South Africa, with the bulk of them located in the Gauteng and Western Cape provinces."

Despite these challenges, companies should be able to compete successfully to capture revenues. Offering a comprehensive range of products offers most companies an edge, especially with regard to winning government tenders. Generic products also have a markedly higher chance of success in the market, particularly with the government-driven shift to generic substitution as a means of reducing healthcare costs.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the South African ophthalmology pharmaceuticals market, then send an email to Patrick Cairns, Corporate Communications, at patrick.cairns[.], with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.

South African Ophthalmology Pharmaceuticals Market is part of the Pharmaceutical & Biotechnology Growth Partnership Service Programme, which also includes research in the following markets: European Ophthalmic Pharmaceuticals Markets, U.S. Leading Ophthalmic Diseases Markets, Pricing and Reimbursement Issues for Pharmaceutical Products in Europe. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

South African Ophthalmology Pharmaceuticals Market - M273

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Frost & Sullivan


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

Ophthalmic Pharmaceuticals Enjoy Good Potential in South Africa

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Patrick Cairns 
+27 18 468 2315 patrick.cairns[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Frost & Sullivan / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  Deb Sheppard - Medium Psychic Author Speaker

Visit  Intrinsic Executive Search Ltd

  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (